Celebrating a Year of Innovation and Growth: MFX's Key Milestones in 2024 and a look ahead to how 2025 is shaping up!

As we kick off 2025, we wanted to take a moment to reflect on the incredible journey we’ve had in 2024. It’s been a whirlwind of innovation, collaboration, and growth. Here’s some of the milestones that have defined our year.?

A Fresh New Identity?

One of the most transformative moments for us in 2024 was rebranding from MicrofluidX to MFX. This change was more than just a new name — it marked the evolution of our technology (and the valuable feedback from our early testers). The Cyto Engine encompasses much more than the microfluidic principles we use to control the cell culture environment and analytics. Our new identity reflects a broader vision, the ability to scale our solutions beyond microfluidics, and our ultimate aim of Cell Therapy ManuFacturing Xccelerated.?

Expanding Horizons Through Global Programs?

This year, we were honoured to participate in cross border initiatives like the Global Innovation Programme to Sweden and the Grow London Programme delegation to Boston. These platforms allowed us to network with industry leaders, form meaningful partnerships worldwide, and set the stage for our global growth ambitions.?

Revolutionary Products in Action?

2024 saw the introduction of the MFX-T and the MFX-12 bioreactors to select partners. The feedback has been overwhelmingly positive:?

“[The MFX-T] is such a simple concept. We were expecting to have to do more optimization, but it showed promising results from the first test.” — MFX Early Access Program Partner?

These two bioreactor cassettes have showcased their potential, delivering remarkable data across multiple cell types and paving the way for the transformative advancements that plug and play automation and online analytics will give to the processes tested.? We're extremely excited to move our partners’ processes to full automation in 2025!?

Collaborating to optimise media using AI?

Before Christmas, we announced our collaboration with Tolemy Bio and AminoAcids.com which uses the MFX-12 bioreactors in the Cyto Engine instrumentation to deliver model-driven media optimization for cell and gene therapies. If you didn’t catch the announcement, here’s the low-down of our exciting new partnership:?

• We’re leveraging the Cyto Engines' high-throughput process development capabilities, Tolemy Bio ’s expertise in AI-enabled media formulation prediction, and AminoAcids.com’s media analytics capabilities to study T-cell cultures.?

• We’re building on the initial Cyto Engine studies using a bio-adaptive feeding strategy to build a comprehensive, AI-powered optimization approach for media formulation.?

• We’re aiming to share our initial findings in the first half of 2025, with the first preview for our newsletter subscribers! Sign up here to keep up to date??

You can find out more in our press release ?? Read the press release???

Or check out the conversation with our VP of Commercial Lindsey Clarke , Tolemy Bio ’s Alex Ward and Caelan Anderson , and AminoAcids.com’s Mark Whittaker below?

Championing Diversity and Inclusion?

Our commitment to diversity and inclusion within the cell and gene therapy (CGT) sector remains unwavering. In 2024, we sponsored the CGT Circle Workshop on Inclusion in June, fostering meaningful conversations and action plans. Additionally, we supported our team members’ involvement in mentoring early-stage professionals beyond the company, reflecting our belief in empowering individual growth and collective progress.? We also welcomed several exceptional interns and students from local colleges, providing them with opportunities to shape their careers in the CGT industry. Their contributions have been invaluable, and we’re thrilled to have played a part in their professional journeys.

Looking Ahead to 2025?

We’re kicking off 2025 with a bang with an exciting press release in the works for later in January!??

Beyond that, the future is bright for MFX as we build further automation and analytical technology into the Cyto Engine.? With the second-generation prototypes of the Cyto Engine, high-throughput process development platform already in our own labs, and we're gearing up to bring the next level of automation and process control to our partners’ processes in 2025.? Building on the success of our early access program, we aim to bring these innovations to the wider industry towards the end of the year.?

If you want to know more about MFX, join our mailing list to keep up to date with our latest news. Alternatively, you can book in a call with one of the team - we're always happy to share our latest developments and get your thoughts on the Cyto Engine's features as we progress from prototypes to products. Book a call with us???